Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TEK | Q02763 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27240085 | 0.89 | KDR (0.41) | SYKEGLN2EGLN1LCKRXFP1 | |
| SCHEMBL27240039 | 0.87 | KDR (0.41) | EGLN1LCKRXFP1KDRMAPKAPK2 | |
| SCHEMBL23287990 | 0.87 | MEN1 (0.39) | EGLN1MAPT | |
| SCHEMBL23287985 | 0.86 | BTK (0.40) | EGLN1LCKRXFP1KDR | |
| SCHEMBL29827331 | 0.82 | GRM5 (0.42) | SYKEGLN2EGLN1RXFP1MAPKAPK2 | |
| SCHEMBL23273849 | 0.82 | GRM5 (0.42) | SYKEGLN2EGLN1RXFP1MAPKAPK2 | |
| SCHEMBL27240172 | 0.82 | GRM5 (0.39) | SYKLCKKDRTEKMAPT | |
| SCHEMBL23287969 | 0.82 | GRM5 (0.45) | EGLN1MAPTRORCEGLN3 | |
| SCHEMBL23273761 | 0.81 | CSF1R (0.42) | — | |
| SCHEMBL27240046 | 0.79 | MEN1 (0.40) | EGLN1RXFP1MAPKAPK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | ONO PHARMACEUTICAL CO., LTD. (JP) | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190824-A1 | INHIBITORS OF TREK (TWIK RELATED K+ CHANNELS) CHANNEL FUNCTION | KCNJ11, KCNJ1, KCNJ2 | SYK 4679/4885EGLN2 1846/4885EGLN1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.